After announcing successful trial results for its lead mRNA treatment earlier this year, Regulus Therapeutics agreed to be ...

Shionogi has reached a JPY 151 billion ($1.04 billion) agreement to buy the pharmaceutical subsidiary of Japan Tobacco, Torii ...

Treatment intensification typically occurs ... Several kidney diseases follow inheritance patterns, including polycystic kidney disease, Alport syndrome, and others. Medical professionals inquire ...

Novartis inks agreement to buy Regulus Therapeutics and farabursen, an investigational microRNA inhibitor to treat ADPKD: Basel Friday, May 2, 2025, 14:00 Hrs [IST] Novartis annou ...

With this approval approximately 45 people[i] living with cystic fibrosis, many with a rare mutation, will be newly eligible for a medicine that ...

Learn about April 2025’s top biotech deals, featuring major collaborations in bispecific antibodies, protein therapies, and ...

Novartis has reached an agreement to buy Regulus Therapeutics and its experimental therapy for autosomal dominant polycystic kidney disease (ADPKD ... one FDA-approved treatment – Otsuka's ...

Do health care providers and even private companies that collect genetic information have an obligation to warn family ...

Reshma Kewalramani; President, Chief Executive Officer, Director; Vertex Pharmaceuticals Inc Stuart Arbuckle; Chief Operating Officer, Executive Vice President; Vertex Pharmaceuticals Inc Good day, ...

GLP-1 receptor agonists remain blockbuster drugs for weight management for people with overweight or obesity. Increasingly, ...

WHEN Chanel Robinson piled on the pounds in the pandemic her self esteem took a hit – but that wasn’t the only downside.